Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC

J Thorac Oncol. 2018 Sep;13(9):e161-e163. doi: 10.1016/j.jtho.2018.04.020. Epub 2018 Apr 25.
No abstract available

Keywords: Afatinib; EGFR triple mutation; Osimertinib; P794L mutation NSCLC.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Afatinib / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / enzymology
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors